AR133161A2 - Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos - Google Patents
Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usosInfo
- Publication number
- AR133161A2 AR133161A2 ARP240101730A ARP240101730A AR133161A2 AR 133161 A2 AR133161 A2 AR 133161A2 AR P240101730 A ARP240101730 A AR P240101730A AR P240101730 A ARP240101730 A AR P240101730A AR 133161 A2 AR133161 A2 AR 133161A2
- Authority
- AR
- Argentina
- Prior art keywords
- cpv
- vlp
- particle
- virus
- canine parvovirus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/135—Foot- and mouth-disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14323—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Vacunas o composiciones contra el parvovirus canino (CPV). La vacuna o composición puede ser una vacuna o composición que contiene una partícula tipo virus (VLP) del CPV y un método de preparación y un uso de la misma. Las VLP del CPV provistas por la invención están formadas por la proteína VP2 del CPV. Además, la invención abarca en general vacunas que comprenden combinaciones de MLV y VLP, que tienen la capacidad para neutralizar las MDA contra una variedad de patógenos, que infectan numerosas especies diferentes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562234196P | 2015-09-29 | 2015-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133161A2 true AR133161A2 (es) | 2025-09-03 |
Family
ID=57003591
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102803A AR106026A1 (es) | 2015-09-29 | 2016-09-14 | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos |
| ARP240101730A AR133161A2 (es) | 2015-09-29 | 2024-07-03 | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102803A AR106026A1 (es) | 2015-09-29 | 2016-09-14 | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10080798B2 (es) |
| EP (2) | EP3355915B1 (es) |
| JP (1) | JP6818748B2 (es) |
| CN (1) | CN108348594B (es) |
| AR (2) | AR106026A1 (es) |
| AU (1) | AU2016332037B2 (es) |
| CA (1) | CA3000352A1 (es) |
| CL (1) | CL2018000820A1 (es) |
| CO (1) | CO2018003460A2 (es) |
| DK (1) | DK3355915T5 (es) |
| ES (1) | ES2974666T3 (es) |
| FI (1) | FI3355915T3 (es) |
| HR (1) | HRP20231630T1 (es) |
| HU (1) | HUE065661T2 (es) |
| LT (1) | LT3355915T (es) |
| MA (1) | MA43016A (es) |
| MX (1) | MX380455B (es) |
| NZ (1) | NZ741875A (es) |
| PL (1) | PL3355915T3 (es) |
| PT (1) | PT3355915T (es) |
| RS (1) | RS65084B1 (es) |
| RU (1) | RU2710854C1 (es) |
| SI (1) | SI3355915T1 (es) |
| WO (1) | WO2017058521A1 (es) |
| ZA (1) | ZA201802117B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3355915T5 (da) * | 2015-09-29 | 2024-09-30 | Boehringer Ingelheim Animal Health Usa Inc | Vacciner af viruslignende partikel (vlp) af hundeparvovirus (cpv) og anvendelser deraf |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| MY201967A (en) | 2017-09-23 | 2024-03-27 | Boehringer Ingelheim Pharma | Paramyxoviridae expression system |
| CN108273055A (zh) * | 2018-01-03 | 2018-07-13 | 复旦大学 | 犬细小病毒疫苗组合物及其制备方法与应用 |
| KR102117810B1 (ko) * | 2018-11-29 | 2020-06-02 | 대한민국(농림축산식품부 농림축산검역본부장) | 재조합 개파보바이러스 2c 항원 단백질 및 이의 용도 |
| CN110157687A (zh) * | 2019-05-25 | 2019-08-23 | 青岛易邦生物工程有限公司 | 一种犬细小病毒三价亚单位疫苗 |
| EP4004035A4 (en) * | 2019-07-30 | 2023-06-28 | Kindred Biosciences, Inc. | Parvovirus antibodies for veterinary use |
| US20220226465A1 (en) | 2021-01-18 | 2022-07-21 | ConserV Bioscience | Coronavirus Immunogenic Compositions, Methods and Uses Thereof |
| CN114317459B (zh) * | 2021-12-31 | 2024-02-23 | 长春西诺生物科技有限公司 | 一种犬瘟热病毒株和基于犬瘟热病毒和犬细小病毒的二联疫苗及应用 |
| CN114957406B (zh) * | 2022-05-26 | 2024-02-02 | 吉林大学 | 一种犬细小病毒的三价抗原和三价病毒样颗粒以及应用 |
| CN116082467A (zh) * | 2022-12-07 | 2023-05-09 | 成都大熊猫繁育研究基地 | 一种基于乙肝病毒c蛋白的犬瘟热重组病毒样颗粒及其疫苗 |
| CN116376981B (zh) * | 2023-04-21 | 2024-11-01 | 西北农林科技大学 | 一种重组犬细小病毒假病毒 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
| US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US4963481A (en) | 1985-12-18 | 1990-10-16 | Genetics Institute Inc | Promoter system |
| EP0260148A3 (en) | 1986-09-12 | 1989-06-07 | Genentech, Inc. | Improved recombinant expression method, vector and transformed cells |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| DE3743138A1 (de) | 1987-12-18 | 1989-09-14 | Mayr Christian Gmbh & Co Kg | Schleifringlose, elektromagnetische ueberlastkupplung |
| US4971793A (en) | 1988-05-09 | 1990-11-20 | Boyce Thompson Institute For Plant Research, Inc. | Subunit canine parvovirus vaccine |
| US6204044B1 (en) | 1989-09-14 | 2001-03-20 | Caroline Sarah Brown | Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines |
| JP3602530B2 (ja) | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | 遺伝子操作したワクチン菌株 |
| CA2214029A1 (en) | 1995-04-25 | 1996-10-31 | Magda Marquet | Single-vial formulations of dna/lipid complexes |
| US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
| FR2751227B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
| FR2751228B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Vaccin polynucleotidique bovin pour voie intradermique |
| FR2751224B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs |
| FR2751225B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
| FR2751229B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
| FR2751226B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies du cheval |
| EP0930893B1 (en) | 1996-10-11 | 2005-04-13 | The Regents of The University of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| CA2223029A1 (en) | 1997-02-12 | 1998-08-12 | Akzo Nobel Nv | Canine parvovirus dna vaccines |
| PL337583A1 (en) | 1997-06-30 | 2000-08-28 | Rhone Poulenc Rorer Sa | Improved method of transferring nucleic acid to a striated muscle and connection enabling accomplishment of this method |
| FR2778858B1 (fr) | 1998-05-20 | 2000-06-16 | Oreal | Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique |
| FR2801607B1 (fr) | 1999-11-26 | 2001-12-28 | Merial Sas | Pneumovirus du canard et vaccins correspondants |
| US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
| US7179456B2 (en) | 2003-04-30 | 2007-02-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Use of parvovirus for brain tumor therapy |
| UA84024C2 (ru) | 2003-07-24 | 2008-09-10 | Мериал Лимитед | Новые вакцинные композиции, которые содержат эмульсию типа "масло в воде" |
| JP2013507925A (ja) | 2009-10-14 | 2013-03-07 | ザ・ボード・オブ・リージェンツ・フォー・オクラホマ・ステート・ユニバーシティ | アライグマからのイヌパルボウイルス−２に関連するウイルスの分離 |
| WO2011127316A1 (en) | 2010-04-07 | 2011-10-13 | Novartis Ag | Method for generating a parvovirus b19 virus-like particle |
| US20120052082A1 (en) * | 2010-04-09 | 2012-03-01 | Zetra Biologicals, LLC | Cross-protective influenza vaccine |
| WO2014016362A1 (en) * | 2012-07-24 | 2014-01-30 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
| CN103387996B (zh) * | 2013-08-19 | 2015-07-15 | 长春西诺生物科技有限公司 | 犬细小病毒病毒样颗粒、其制备方法及应用 |
| CN103409377B (zh) * | 2013-08-28 | 2015-12-23 | 中国农业科学院兰州兽医研究所 | 犬细小病毒病毒样颗粒的制备及用途 |
| DK3355915T5 (da) * | 2015-09-29 | 2024-09-30 | Boehringer Ingelheim Animal Health Usa Inc | Vacciner af viruslignende partikel (vlp) af hundeparvovirus (cpv) og anvendelser deraf |
-
2016
- 2016-09-14 DK DK16771050.8T patent/DK3355915T5/da active
- 2016-09-14 AU AU2016332037A patent/AU2016332037B2/en active Active
- 2016-09-14 RS RS20240073A patent/RS65084B1/sr unknown
- 2016-09-14 MA MA043016A patent/MA43016A/fr unknown
- 2016-09-14 MX MX2018004016A patent/MX380455B/es unknown
- 2016-09-14 FI FIEP16771050.8T patent/FI3355915T3/fi active
- 2016-09-14 HR HRP20231630TT patent/HRP20231630T1/hr unknown
- 2016-09-14 NZ NZ741875A patent/NZ741875A/en unknown
- 2016-09-14 LT LTEPPCT/US2016/051736T patent/LT3355915T/lt unknown
- 2016-09-14 JP JP2018516415A patent/JP6818748B2/ja active Active
- 2016-09-14 WO PCT/US2016/051736 patent/WO2017058521A1/en not_active Ceased
- 2016-09-14 HU HUE16771050A patent/HUE065661T2/hu unknown
- 2016-09-14 CA CA3000352A patent/CA3000352A1/en active Pending
- 2016-09-14 EP EP16771050.8A patent/EP3355915B1/en active Active
- 2016-09-14 AR ARP160102803A patent/AR106026A1/es active IP Right Grant
- 2016-09-14 PT PT167710508T patent/PT3355915T/pt unknown
- 2016-09-14 ES ES16771050T patent/ES2974666T3/es active Active
- 2016-09-14 CN CN201680065340.XA patent/CN108348594B/zh active Active
- 2016-09-14 US US15/265,545 patent/US10080798B2/en active Active
- 2016-09-14 EP EP23190361.8A patent/EP4286002A3/en active Pending
- 2016-09-14 SI SI201631795T patent/SI3355915T1/sl unknown
- 2016-09-14 RU RU2018115796A patent/RU2710854C1/ru active
- 2016-09-14 PL PL16771050.8T patent/PL3355915T3/pl unknown
-
2018
- 2018-03-28 CO CONC2018/0003460A patent/CO2018003460A2/es unknown
- 2018-03-29 CL CL2018000820A patent/CL2018000820A1/es unknown
- 2018-04-03 ZA ZA2018/02117A patent/ZA201802117B/en unknown
- 2018-08-22 US US16/109,570 patent/US10537632B2/en active Active
-
2024
- 2024-07-03 AR ARP240101730A patent/AR133161A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR133161A2 (es) | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos | |
| WO2017191258A8 (en) | INFLUENZA MRNA VACCINES | |
| MX2022006603A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
| MX373792B (es) | Coronavirus. | |
| MX2019004593A (es) | Vectores recombinantes que expresan antigenos de virus de influenza aviar y usos de los mismos. | |
| MX2017003946A (es) | Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana. | |
| EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
| WO2016207853A3 (en) | Antigenically matched influenza vaccines | |
| SG11202005251VA (en) | Formulations of dengue virus vaccine compositions | |
| ZA202403393B (en) | Synthetic chimeric poxviruses | |
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| MX383330B (es) | Particula tipo virus de flavivirus. | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| CU20180025A7 (es) | Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue | |
| MX2017005687A (es) | Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia. | |
| MX382530B (es) | Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos. | |
| PH12018501368A1 (en) | M hyo multivalent vaccine and uses thereof | |
| PH12017501100A1 (en) | Recombinant swinepox virus and vaccines | |
| CO7461135A2 (es) | Parvovirus porcino 5b, métodos de uso y vacuna | |
| IL259451B (en) | A live virus containing an attenuated dengue virus and a dengue vaccine containing identical antigens | |
| AR094912A1 (es) | Vacuna contra el virus de la leucemia bovina | |
| MX2024007379A (es) | Vacunas para el virus del papiloma humano y metodos para su uso. | |
| HK40034325A (en) | Formulations of dengue virus vaccine compositions | |
| AR108664A1 (es) | Vacuna contra la bronquitis infecciosa | |
| MX390292B (es) | Vacuna heterologa atenuada viva para leptospira. |